PHARMACOTHERAPY
MAMMOLOGY. TOPICAL ISSUE
In recent years, it has been demonstrated that breast cancer arising in BRCA1 and BRCA2 mutation carriers differs in its morphological, immuno- phenotypic and molecular characteristics from sporadic breast cancer. In addition to improving our understanding of the biology of hereditary breast cancer, the recognition of these differences could also be used to predict BRCA mutation status in a given group of patients.
The authors assert that active sanitary-educational work, increase of women’s knowledge about oncological diseases, propagation of healthy way of life, working out and introduction of screening programs, and also revealing of risk factors with formation of groups of risk, will allow to reveal and spend in due time adequate treatment of diseases, having changed thereby an epidemiological situation in Tajikistan towards decrease in disease and death rate of women from malignant tumors of the organs of reproductive system.
MAMMOLOGY. DIAGNOSIS
MAMMOLOGY. TREATMENT
The paper considers main surgical interventions used to treat breast cancer. It defines the role and place of conservative surgery and describes current procedures for the organ-saving treatment of cancer at this site.
GYNECOLOGY. DIAGNOSIS
Twenty-five patients with atypical endometrial hyperplasia (AEH) and 90 patients with Stages I-II endometrial cancer (EC) were followed up. The patients’ mean age was 44.3±2.1 years. A control group consisted of 20 healthy women matched for age. Before treatment, the authors determined the blood levels of adrenocorticotropic hormone and cortisol by radiometric assay and the content of daily excreted cortisol, cortisone, tetrahydrocortisol, tetrahydrocortisone, 11-hydroxy-17-ketosteroids, estrone, estradiol, and pregnanediol by the conventional classical studies.
The nature of the impaired synthesis and metabolism of sex and adrenocorticoid hormones and their degree have been found to coincide, which suggest that it is expedient to use these findings to form EC risk groups in patients with AEH in the late reproductive period.
GYNECOLOGY. TREATMENT
The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime.
GYNECOLOGY. ORIGINAL ISSUES
Fixation of the preserved ovaries to uterine round ligament allow to retain ovarian function, not only during postoperative radiotherapy of stage Ib cervical cancer due to their transposition, but also after completing pelvic radiation because of preserved ovarian blood vessels in physiological place. This method prevents surgical and radiologic castration.
ISSN 1999-8627 (Online)